Hitting multiple targets with multimeric ligands

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 6, 2004, Pages 565-586

  Handl, Heather L ^a   Vagner, Josef ^a   Han, Haiyong ^a   Mash, Eugene ^a   Hruby, Victor J ^a   Gilles, Robert J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Avidity; Binding; Cancer; Cooperativity; Ligand; Molecular markers; Multimeric; Multimeric ligand design; Multivalent; Polyvalency; Targeted therapy

Indexed keywords

ANTIBODY; BOMBESIN; BOMBESIN RECEPTOR; BRADYKININ ANTAGONIST; BRADYKININ RECEPTOR; CARBOHYDRATE DERIVATIVE; DNA; DOUBLE STRANDED DNA; GLUTATHIONE TRANSFERASE; GONADORELIN RECEPTOR; INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; INTEGRIN; LECTIN RECEPTOR; LIGAND; LIPOSOME; MELANOCORTIN RECEPTOR; METHOTREXATE; NALTREXAMINE; NALTREXONE; OPIATE RECEPTOR; PEPTIDE FRAGMENT; POLYMER; PROTEIN KINASE C; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN DERIVATIVE; SUMATRIPTAN; UNINDEXED DRUG; VANCOMYCIN;

BINDING AFFINITY; BINDING KINETICS; CELL SURFACE; DNA BINDING; DNA HYBRIDIZATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SELECTIVITY; DRUG TARGETING; ENCAPSULATION; ENTHALPY; ENTROPY; HUMAN; IN VITRO STUDY; LIGAND BINDING; NONHUMAN; REVIEW; SCANNING ELECTRON MICROSCOPY; THERMODYNAMICS;

ANTINEOPLASTIC AGENTS; DNA; DRUG CARRIERS; DRUG DESIGN; KINETICS; LIGANDS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NUCLEIC ACID DENATURATION; NUCLEIC ACID HYBRIDIZATION; POLYMERS; PROTEIN BINDING; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THERMODYNAMICS;

EID: 11144317860     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.6.565     Document Type: Review

References (93)

1. VAGNER J, HANDL HL, GILLIES RJ, HRUBY VJ: Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of [alpha]-MSH. Bioorg. Med. Chem. Lett. (2004) 14:211-215.
2. PLUCKTHUN A, PACK P: New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology (1997) 3:83-105.
3. TODOROVSKA A, ROOVERS RC, DOLEZAL O, KORTT AA, HOOGENBOOM HR, HUDSON PJ: Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods (2001) 248 47-66.
4. DAM TK, ROY R, DAS SK, OSCARSON S, BREWER CF: Binding of multivalent carbohydrates to concanavalin A and Dioclea grandiflora lectin - thermodynamic analysis of the 'multivalency effect'. J. Biol. Chem. (2000) 275:14223-14230.
5. LESTINI BJ, SAGNELLA SM, XU Z et al.: Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J. Control. Release (2002) 78:235-247.
6. JANSSEN AP, SCHIFFELERS RM, TEN HAGEN TL et al.: Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int. J. Pharm. (2003) 254:55-58.
7. MOREIRA JN, HANSEN CB, GASPAR R, ALLEN TM: A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim. Biophys. Acta (2001) 1514 303-317.
8. SCHWYZER R, KRIWACZEK VM: Tobacco mosaic-virus as a carrier for small molecules - artificial receptor antibodies and super-hormones. Biopolymers (1981) 20:2011-2020.
9. KRIWACZEK VM, SCHWYZER R, GILLAN MG, PATERSON SJ, KOSTERLITZ HW: Tobacco mosaic virus-enkephalin conjugates - potentiation of opioid activity. Peptides (1981) 2:89-92.
10. MONOD J, CHANGEUX JP, JACOB F: Allosteric proteins and cellular control systems. J. Mol. Biol. (1963) 6:306-329.
11. INMAN GJ, HILL CS: Stoichiometry of active smad-transcription factor complexes on DNA. J. Biol. Chem. (2002) 277 51008-51016.
12. LORTAT-JACOB H, CHOUIN E, CUSACK S, VAN RAAIJ MJ: Kinetic analysis of adenovirus fiber binding to its receptor reveals an avidity mechanism for trimeric receptor-ligand interactions. J. Biol Chem. (2001) 276:9009-9015.
13. GESTWICKI JE, STRONG LE, KIESSLING LL: Tuning chemotactic responses with synthetic multivalent ligands. Chem. Biol. (2000) 7:583-591.
14. ARRANZ-PLAZA E, TRACY AS, SIRIWARDENA A, PIERCE JM, BOONS GJ: High-avidity, low-affinity multivalent interactions and the block to polyspermy in Xenopus laevis. J. Am. Chem. Soc. (2002) 124 13035-13046.
15. CROTHERS DM, METZGER H: Influence of polyvalency on binding properties of antibodies. Immunochemistry (1972) 9:341-357.
16. MAMMEN M, CHOI S-K, WHITESIDES GM: Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. (1998) 37:2754-2796.
17. KIESSLING LL, GESTWICKI JE, STRONG LE: Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr. Opin. Chem. Biol. (2000) 4:696-703.
18. LUNDQUIST JJ, TOONE EJ: The cluster glycoside effect. Chem. Rev. (2002) 102:555-578.
19. LEE YC, LEE RT: Enhanced biochemical affinities of multivalent neoglycoconjugates. In: Neoglycoconjugates: preparation and applications. Lee YC, Lee RT (Eds), Academica Press, San Diego, USA (1994):23-50.
20. FULTON DA, CANTRILL SJ, STODDART JF: Probing polyvalency in artificial systems exhibiting molecular recognition. J. Org. Chem. (2002) 67:7968-7981.
21. VERRECCHIO A, GERMANN MW, SCHICK BP, KUNG B, TWARDOWSKI T, SAN ANTONIO JD: Design of peptides with high affinities for heparin and endothelial cell proteoglycans. J. Biol. Chem. (2000) 275 7701-7707.
22. SHARMA SD, GRANBERRY ME, JIANG J, LEONG SP, HADLEY ME, HRUBY VJ: Multivalent melanotropic peptide and fluorescent macromolecular conjugates: new reagents for characterization of melanotropin receptors. Bioconjug. Chem. (1994) 5:591-601.
23. JIANG J, SHARMA SD, HRUBY VJ, BENTLEY DL, FINK JL, HADLEY ME: Human epidermal melanocyte and keratinocyte melanocortin receptors: visualization by melanotropic peptide conjugated microspheres (latex beads). Pigment Cell Res. (1996) 9:240-247.
24. SHARMA SD, JIANG JW, HADLEY ME, BENTLEY DL, HRUBY VJ: Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. Proc. Natl. Acad. Sci. USA (1996) 93:13715-13720.
25. JIANG J, SHARMA SD, HRUBY VJ, FINK JL, HADLEY ME: Human epidermal melanocyte and keratinocyte melanotropin receptors: visualization by melanotropic peptide conjugated macrospheres (polymide beads). Exp. Dermatol. (1997) 6:6-12.
26. GESTWICKI JE, CAIRO CW, STRONG LE, OETJEN KA, KIESSLING LL: Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J. Am. Chem. Soc. (2002) 124:14922-14933.
27. KIESSLING LL, STRONG LE, GESTWICKI JE: Principles for multivalent ligand design. Annu. Rep. Med. Chem. (2000) 35 321-330.
28. FAN EK, ZHANG ZS, MINKE WE, HOU Z, VERLINDE CL, HOL WG: High-affinity pentavalent ligands of Escherichia coli heat- labile enterotoxin by modular structure-based design. J. Am. Chem. Soc. (2000) 122:2663-2664.
29. KRAMER RH, KARPEN JW: Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature (1998) 395 710-713.
30. ZHANG ZS, MERRITT EA, AHN M et al.: Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J. Am. Chem. Soc. (2002) 124 12991-12998.
31. LOIDL G, MUSIOL HJ, GROLL M, HUBER R, MORODER L: Synthesis of bivalent inhibitors of eucaryotic proteasomes. J. Pept. Sci. (2000) 6:36-46.
32. RAO JH, LAHIRI J, ISAACS L, WEIS RM, WHITESIDES GM: A trivalent system from vancomycin center dot D-Ala-D-Ala with higher affinity than avidin center dot biotin. Science (1998) 280 708-711.
33. HRUBY VJ, MOSBERG HI: Conformational and dynamic considerations in peptide structure-function studies*1. Peptides (1982) 3:329-336.
34. BOESCH C, BUNDI A, OPPLIGER M, WUTHRICH K: 1H nuclear-magnetic-resonance studies of the molecular conformation of monomeric glucagon in aqueous solution. Eur. J. Biochem. (1978) 91:209-214.
35. PULLEN RA, JENKINS JA, TICKLE IJ, WOOD SP, BLUNDELL TL: The relation of polypeptide hormone structure and flexibility to receptor binding: the relevance of X-ray studies on insulins, glucagon and human placental lactogen. Mol. Cell. Biochem. (1975) 8:5-20.
36. WEIDLER M, MARX UC, SEIDEL G et al.: The structure of human parathyroid hormone-related protein(1-34) in near-physiological solution. FEBS Lett. (1999) 444:239-244.
37. HORAN N, YAN L, ISOBE H, WHITESIDES GM, KAHNE D: Nonstatistical binding of a protein to clustered carbohydrates. Proc. Natl. Acad. Sci. USA (1999) 96:11782-11786.
38. CAIRO CW, GESTWICKI JE, KANAI M, KIESSLING LL: Control of multivalent interactions by binding epitope density. J. Am. Chem. Soc. (2002) 124:1615-1619.
39. HOUSEMAN BT, MRKSICH M: Model systems for studying polyvalent carbohydrate binding interactions. Host-Guest Chemistry (2002) 218:1-44.
40. BAUMGART T, HESS ST, WEBB WW: Imaging coexisting fluid domains in biomembrane models coupling curvature and line tension. Nature (2003) 425:821-824.
41. SHEETS ED, SIMSON R, JACOBSON K: New insights into membrane dynamics from the analysis of cell surface interactions by physical methods. Curr. Opin. Cell Biol. (1995) 7:707-714.
42. JACOBSON K, DERZKO Z, WU ES, HOU Y, POSTE G: Measurement of the lateral mobility of cell surface components in single, living cells by fluorescence recovery after photobleaching. J. Supramol. Struct. (1976) 5:565-576.
43. SHEETZ MP, TURNEY S, QIAN H, ELSON EL: Nanometer-level analysis demonstrates that lipid flow does not drive membrane glycoprotein movements. Nature (1989) 340:284-288.
44. SAKO Y, KUSUMI A: Compartmentalized structure of the plasma membrane for receptor movements as revealed by a nanometer-level motion analysis. J. Cell Biol. (1994) 125:1251-1264.
45. MARMUR J, ROWND R, SCHILDKRAUT CL: Denaturation and renaturation of deoxyribonucleic acid. Prog. Nucleic Acid Res. Mol. Biol. (1963) 1:231-300.
46. DEVOE H, TINOCO I: Stability of helical polynucleotides - base contributions. J. Mol. Biol. (1962) 4:500-517.
47. WETMUR JG: DNA probes: applications of the principles of nucleic acid hybridization. Crit. Rev. Biochem. Mol. Biol. (1991) 26:227-259.
48. PULLMAN B, PULLMAN A: The electronic structure of the purine-pyrimidine pairs of DNA. Biochim. Biophys. Acta (1959) 36 343-350.
49. WETMUR JG: Hybridization and renaturation kinetics of nucleic-acids. Annu. Rev. Biophys. Bioeng. (1976) 5:337-361.
50. WETMUR JG, DAVIDSON N: Kinetics of renaturation of DNA. J. Mol. Biol. (1968) 31:349-370.
51. GILLIES RJ, HRUBY VJ: Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin. Ther. Targets (2003) 7:137-139.
52. PARKHURST KM, PARKHURST LJ: Kinetic-studies by fluorescence resonance energy-transfer employing a double-labeled oligonucleotide - hybridization to the oligonucleotide complement and to single-stranded-DNA. Biochemistry (1995) 34:285-292.
53. GARGANO JM, NGO T, KIM JY, ACHESON DW, LEES WJ: Multivalent inhibition of AB(5) toxins. J. Am. Chem. Soc. (2001) 123 12909-12910.
54. JENCKS WP: On the attribution and additivity of binding-energies. Proc. Natl. Acad. Sci. USA (1981) 78 4046-4050.
55. CHRISTENSEN T, GOODEN DM, KUNG JE, TOONE EJ: Additivity and the physical basis of multivalency effects: a thermodynamic investigation of the calcium EDTA interaction. J. Am. Chem. Soc. (2003) 125 7357-7366.
56. BRESLAUER KJ, FRANK R, BLOCKER H, MARKY LA: Predicting DNA duplex stability from the base sequence. Proc. Natl. Acad. Sci. USA (1986) 83:3746-3750.
57. BRITTEN RJ, KOHNE DE: Repeated sequences in DNA. Hundreds of thousands of copies of DNA sequences have been incorporated into the genomes of higher organisms. Science (1968) 161:529-540.
58. GRIFFIN TJ, SMITH LM: An approach to predicting the stabilities of peptide nucleic acid:DNA duplexes. Anal. Biochem. (1998) 260:56-63.
59. KAPTAIN S, TAN LK, CHEN B: Her-2/neu and breast cancer. Diagn. Mol. Pathol. (2001) 10:139-152.
60. LOIDL G, GROLL M, MUSIOL HJ, HUBER R, MORODER L: Bivalency as a principle for proteasome inhibition. PNAS (1999) 96 5418-5422.
61. CASASNOVAS J, SPRINGER TA: Kinetics and thermodynamics of virus binding to receptor. J. Biol. Chem. (1995) 270 13216-13224.
62. MATROSOVICH MN: Towards the development of antimicrobial drugs acting by inhibition of pathogen attachment to host cells: a need for polyvalency. FEBS Lett. (1989) 252:1-4.
63. CHAN D, GERA L, STEWART J et al.: Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a 'biased agonist'mechanism. Proc. Natl. Acad. Sci. USA (2002) 99 4608-4613.
64. HALAZY S, PEREZ M, FOURRIER C et al.: Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT1B/1D agonists. J. Med. Chem. (1996) 39 4920-4927.
65. PEREZ M, PAUWELS PJ, FOURRIER C et al.: Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist. Bioorg. Med. Chem. Lett. (1998) 8 675-680.
66. PORTOGHESE PS, RONSISVALLE G, LARSON DL, YIM CB, SAYRE LM, TAKEMORI AE: Opioid agonist and antagonist bivalent ligands as receptor probes. Life Sci (1982) 31:1283-1286.
67. EREZ M, TAKEMORI AE, PORTOGHESE PS: Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine - evidence for bridging between proximal recognition sites. J. Med. Chem. (1982) 25:847-849.
68. CARRITHERS MD, LERNER MR: Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors. Chem. Biol. (1996) 3:537-542.
69. BOLOGNESI M, OJALA WH, GLEASON WB et al.: Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide "address" recognition at kappa opioid receptors. J. Med. Chem. (1996) 39:1816-1822.
70. CONN PM, ROGERS DC, MCNEIL R: Potency enhancement of a Gnrh agonist - Gnrh-receptor microaggregation stimulates gonadotropin in release. Endocrinology (1982) 111:335-337.
71. DANILOV YN, JULIANO RL: (Arg-Gly-Asp)N-albumin conjugates as a model substratum for integrin-mediated cell-adhesion. Exp. Cell Res. (1989) 182:186-196.
72. SRIDHAR J, WEI ZL, NOWAK I et al.: New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity. J. Med. Chem. (2003) 46:4196-4204.
73. RILEY AM, LAUDE AJ, TAYLOR CW, POTTER BV: Dimers of D-myo-inositol 1,4,5-trisphosphate: design, synthesis, and interaction with ins(1,4,5)P-3 receptors. Bioconjugate Chemistry (2004) 15 278-289.
74. 3-binding sites. J. Biol. Chem. (2002) 277 40290-40295.
75. BOTURYN D, COLL JL, GARANGER E, FAVROT MC, DUMY P: Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J. Am. Chem. Soc. (2004) 126:5730-5739.
76. MIYAZAKI M, KODAMA H, FUJITA I, HAMASAKI Y, MIYAZAKI S, KONDO M: Dimeric chemotactic peptides discriminate between chemotaxis and superoxide production of human neutrophils. J. Biochem. (1995) 117:489-494.
77. MENGER FM, BIAN JW, SIZOVA E, MARTINSON DE, SEREDYUK VA: Bolaforms with fourteen galactose units: a proposed site-directed cohesion of cancer cells. Organic Letters (2004) 6:261-264.
78. SCHASCHKE N, MATSCHINER G, ZETTL F et al.: Bivalent inhibition of human [Beta]-tryptase. Chem. Biol. (2001) 8 313-327.
79. MAYNARD HD, OKADA SY, GRUBBS RH: Inhibition of cell adhesion to fibronectin by oligopeptide-substituted polynorbornenes. J. Am. Chem. Soc. (2001) 123:1275-1279.
80. LYON RP, HILL JJ, ATKINS WM: Novel class of bivalent glutathione S-transferase inhibitors. Biochemistry (2003) 42 10418-10428.
81. KODAMA H, SHIMOHIGASHI Y, SAKAGUCHI K et al.: Dimerization of neurokin A and B COOH-terminal heptapeptide fragments enhanced the selectivity for tachykinin receptor subtypes. Eur. J. Pharmacol. (1988) 151:317-320.
82. SHUKER SB, HAJDUK PJ, MEADOWS RP, FESIK SW: Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 274:1531-1534.
83. KOPYTEK SJ, STANDAERT RF, DYER JC, HU JC: Chemically induced dimerization of dihydrofolate reductase by a homobifunctional dimer of methotrexate. Chem. Biol. (2000) 7:313-321.
84. QIN DH, SULLIVAN R, BERKOWITZ WF, RITTMAN R, ROTENBERG SA: Inhibition of protein kinase C alpha by dequalinium analogues: dependence on linker length and geometry. J. Med. Chem. (2000) 43 1413-1417.
85. DEKKER FJ, DE MOL NJ, FISCHER MJ, LISKAMP RM: Amino propynyl benzoic acid building block in rigid spacers of divalent ligands binding to the Syk SH2 domains with equally high affinity as the natural ligand. Bioorg. Med. Chem. Lett. (2003) 13:1241-1244.
86. SUNDARAM R, SUN Y, WALKER CM, LEMONNIER FA, JACOBSON S, KAUMAYA PT: A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. Vaccine (2003) 21 2767-2781.
87. CHERONIS JC, WHALLEY ET, NGUYEN KT et al.: A new class of bradykinin antagonists - synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J. Med. Chem. (1992) 35 1563-1572.
88. GRIFFIN JH, LINSELL MS, NODWELL MB et al.: Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. J. Am. Chem. Soc. (2003) 125:6517-6531.
89. HAN YF, LI CP, CHOW E, WANG H, PANG YP, CARLIER PR: Dual-site binding of bivalent 4-aminopyridine and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities. Bioorg. Med. Chem. (1999) 7:2569-2575.
90. MOHAN P, WONG MF, VERMA S, HUANG PP, WICKRAMASINGHE A, BABA M: Structure-activity relationship studies with symmetric naphthalenesulfonic acid derivatives. Synthesis and influence of spacer and naphthalenesulfonic acid moiety on anti-HIV-1 activity. J. Med. Chem. (1993) 36:1996-2003.
91. KITOV PI, SADOWSKA JM, MULVEY G et al.: Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature (2000) 403:669-672.
92. LEBOULLUEC KL, MATTSON RJ, MAHLE CD, MCGOVERN RT, NOWAK HP, GENTILE AJ: Bivalent indoles exhibiting serotonergic binding affinity. Bioorg. Med. Chem. Lett. (1995) 5:123-126.
93. BAIRD EJ, HOLOWKA D, COATES GW, BAIRD B: Highly effective poly(ethylene glycol) architectures for specific inhibition of immune receptor activation. Biochemistry (2003) 42:12739-12748.